食管癌前病变的内镜监测:基于社区的多中心前瞻性队列研究
该研究纳入中国农村9个地区2010至2016年社区食管鳞癌筛查中检出的1183例轻中度异型增生患者,随访至2021年12月。中位随访6.95年,88例(7.44%)进展为晚期肿瘤,发病率为10.44/1000人年,中位进展间隔2.39年。结论建议轻中度异型增生患者在前2至3年内接受内镜监测。
要点
- 轻中度异型增生患者晚期肿瘤进展率为7.44%,发病率为10.44/1000人年。
- 74.47%的患者逆转为非异型增生,18.09%无病变进展。
- 有食管癌家族史且年龄≥55岁的患者晚期肿瘤检出率比所有轻中度异型增生患者高97%。
核心结论
- 在食管鳞癌高发国家,轻中度异型增生患者晚期肿瘤进展的总体风险为每年1.04%。
- 建议轻中度异型增生患者在前2至3年内接受内镜监测。
研究设计与样本
- 前瞻性队列研究,纳入中国农村9个地区2010至2016年社区食管鳞癌筛查项目中检出的轻中度异型增生患者1183例,随访至2021年12月。
主要发现
- 1183例轻中度异型增生患者随访6.95年期间,88例(7.44%)进展为晚期食管肿瘤,发病率为10.44/1000人年。
- 从轻中度异型增生进展至晚期肿瘤的中位间隔为2.39年(四分位距1.58-4.32年)。
- 74.47%的轻中度异型增生患者逆转为非异型增生,18.09%无病变进展。
- 有食管癌家族史且年龄≥55岁的轻中度异型增生患者,晚期肿瘤检出率比所有轻中度异型增生患者高97%。
临床怎么用
- 作者建议轻中度异型增生患者在前2至3年内接受内镜监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Mild and moderate dysplasia are major premalignant lesions of esophageal squamous cell carcinoma (ESCC); however, evidence of the progression risk in patients with these conditions is extremely limited. We aimed to assess the incidence and risk factors for advanced neoplasia in patients with mild-moderate dysplasia. METHODS: This prospective cohort study included patients with mild-moderate dysplasia from 9 regions in rural China. These patients were identified from a community-based ESCC screening program conducted between 2010 and 2016 and were offered endoscopic surveillance until December 2021. We estimated the incidence of advanced esophageal neoplasia, including severe dysplasia, carcinoma in situ, or ESCC, and identified potential risk factors using the Cox regression model. RESULTS: The 1183 patients with mild-moderate dysplasia were followed up over a period of 6.95 years. During follow-up evaluation, 88 patients progressed to advanced neoplasia (7.44%), with an incidence rate of 10.44 per 1000 person-years. The median interval from the progression of mild-moderate dysplasia to advanced neoplasia was 2.39 years (interquartile range, 1.58-4.32 y). A total of 74.47% of patients with mild-moderate dysplasia experienced regression to nondysplasia, and 18.09% showed no lesion progression. Patients with mild-moderate dysplasia who had a family history of esophageal cancer and were age 55 years and older showed 97% higher advanced neoplasia yields than all patients with mild-moderate dysplasia. CONCLUSIONS: In a country with a high incidence of ESCC, patients with mild-moderate dysplasia showed an overall risk of advanced neoplasia progression of 1.04% per year. Patients with mild-moderate dysplasia would be recommended for endoscopic surveillance during the first 2 to 3 years.
引用
- Li H, Zhang S, Zhou J, et al. Endoscopic Surveillance for Premalignant Esophageal Lesions: A Community-Based Multicenter, Prospective Cohort Study. Clin Gastroenterol Hepatol. 2022. PMID: 35623589. doi:10.1016/j.cgh.2022.04.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。